scholarly journals Prevalence of metabolic syndrome in non-obese newly detected Type-2 diabetes Mellitus

2016 ◽  
Vol 9 (1) ◽  
pp. 26
Author(s):  
Mahbooba Akhter ◽  
Afsana Ahmed ◽  
Mahbubor Rahman ◽  
Roksana Malek ◽  
Azmeri Alam ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
Preventive Strategy ◽  
Cross Sectional ◽  
The Metabolic Syndrome ◽  
Type 2 Dm ◽  
Medical University

<p><strong>B</strong><strong>ackground</strong><strong>: </strong>The metabolic syndrome is driving twin global epidemics; type 2 diabetes mellitus and cardiovascular disease. There is an overwhelming moral, medical, and economic imperative to identify those individuals with metabolic syndrome. Regarding this issue, non obese individuals are given less attention and ultimately situation becomes grievous therefore.</p><p><strong>Ob</strong><strong>j</strong><strong>ective</strong><strong>: </strong>To assess the prevalence of metabolic syndrome in non–obese newly detected type 2 DM patient. Method: This cross sectional analytical study was carried out in the department of Biochemistry, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Total 209 cases (165 male &amp; 44 female) were selected from BIRDEM. Statistical analysis and data management were carried out using the SPSS (Version 12.0).</p><p><strong>R</strong><strong>esult</strong><strong>: </strong>In this study, prevalence rates of metabolic syndrome were 60.3% (53.3% male, 86.4% female), 58.9% (57.0% male, 65.9% female) and 26.3% (15.8% male, 65.9% female) according to modified National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III), modified WHO &amp; IDF criteria respectively.</p><p><strong>Conclusion</strong><strong>: </strong>Prevalence of metabolic syndrome in non-obese newly detected Type 2 DM is very high &amp; Prevalence of metabolic syndrome in non-obese newly detected Type 2 DM found significantly higher in female than male. Adequate realistic steps of preventive strategy are of urgent need to combat this high prevalence of metabolic syndrome in non-obese diabetic people.</p>

scholarly journals A Comparison of the Prevalence of the Metabolic Syndrome among Sri Lankan Patients with Type 2 Diabetes Mellitus Using WHO, NCEP-ATP III, and IDF Definitions

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
H. M. M. Herath ◽  
N. P. Weerasinghe ◽  
T. P. Weerarathna ◽  
A. Amarathunga
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
The Metabolic Syndrome ◽  
Type 2 Dm ◽  
Cardiovascular Morbidity And Mortality ◽  
The Mean ◽  
The Difference

Background. Presence of metabolic syndrome (MetS) in patients with type 2 diabetes mellitus (type 2 DM) increases the risk of cardiovascular morbidity and mortality. Therefore, recognition of MetS in type 2 DM is important in initiating the appropriate preventive and therapeutic measures. The commonly used definitions have similarities and discrepancies. Aims of this study was to investigate the prevalence of MetS among patients with type 2DM using all three well known (WHO, IDF, and NCEP-ATP III) definitions and to identify the concordance and the difference of these three definitions. Methods. This cross-sectional study included patients with type 2 DM who were followed up at the regional diabetes centre in Galle, Sri Lanka. A total of 2913 type 2 DM patients were recruited by convenient sampling method, and their clinical and biochemical data were collected. Results. The mean age (SD) of the sample was 49.9 (10.2) years and the mean duration of diabetes was 5.04 (5.71). Prevalence of MetS was highest by WHO (70%) followed by IDF (44%) and NCEP-ATP III (29%) definitions. The prevalence was significantly higher in women according to all three definitions, and the difference was most marked with NCEP-ATP III and IDF definitions. Around 25% were identified as having MetS by all three definitions whereas around 45% were recognized with MetS by two definitions. While concordances between WHO with IDF (0.37, p < 0.001) and NCEP-ATP III (0.24, p < 0.001) criteria were poor, they were average (0.53, p < 0.001) between NCEP-ATP III and IDF criteria. Conclusions. The prevalence of MetS among patients with type 2 DM can significantly be varied based on the definition used and the three definitions of MetS recognized different set of individuals. The highest prevalence of MetS was observed with WHO (70.6%) whereas lowest was observed with NCEP-ATP III definition.

scholarly journals The Tri-ponderal Mass Index is associated with adiposity in adolescent type 2 diabetes mellitus: a cross-sectional analysis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Haifa Alfaraidi ◽  
Brandy Wicklow ◽  
Allison B. Dart ◽  
Elizabeth Sellers ◽  
Jonathan McGavock ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
Secondary Data ◽  
P Value ◽  
Z Score ◽  
Cross Sectional ◽  
The Metabolic Syndrome

AbstractPediatric type 2 diabetes mellitus (T2DM) patients are often overweight or obese, yet there are no validated clinical measures of adiposity to stratify cardiometabolic risk in this population. The tri-ponderal mass index (TMI, kg/m3) has recently been reported as a measure of adiposity in children, but there has been no validation of the association of TMI with adiposity in pediatric T2DM. We hypothesized that in children with T2DM, the TMI can serve as a more accurate measure of adiposity when compared to BMI z-score, and that it is associated with components of the metabolic syndrome. This is a cross-sectional secondary data analysis from the Improving Renal Complications in Adolescents with Type 2 Diabetes Through REsearch (iCARE) study (n = 116, age 10.20–17.90 years). Spearman’s correlations and multivariable regression were used in the analyses. When compared to DXA, TMI demonstrated significant correlation with total adiposity versus BMI z-score (TMI r = 0.74, p-value < 0.0001; BMI z-score r = − 0.08, p-value 0.403). In regression analyses, TMI was associated with WHtR (B = 35.54, 95% CI 28.81, 42.27, p-value < 0.0001), MAP dipping (B = 1.73, 95% CI 0.12, 3.33, p-value = 0.035), and HDL (B = − 5.83, 95% CI − 10.13, − 1.54, p-value = 0.008). In conclusion, TMI is associated with adiposity and components of the metabolic syndrome in pediatric T2DM patients.

scholarly journals Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout

2020 ◽  
Vol 92 (5) ◽  
pp. 110-118 ◽  
Author(s):  
T. S. Panevin ◽  
M. S. Eliseev ◽  
M. V. Shestakova ◽  
E. L. Nasonov
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
New Drugs ◽  
Positive Effects ◽  
The Metabolic Syndrome ◽  
Sodium Glucose Cotransporter ◽  
The Russian Federation

Currently, only two drugs for reducing uric acid (UA), allopurinol and febuxostat, are registered in the Russian Federation, but their use does not allow to achieve the target level of UA in all cases. According to the results of numerous randomized trials, hyperuricemia and gout are associated with the corresponding components of the metabolic syndrome, including diabetes mellitus. The influence of factors is due to the need to search for new drugs that have a complex effect on several components of metabolic syndrome at once. Potentially attractive in this regard is a new group of drugs for the treatment of type 2 diabetes mellitus inhibitors of the sodium-glucose cotransporter of type 2, which, in addition to the main hypoglycemic actions, showed positive effects on the cardiovascular system, kidneys, as well as lowering UA.

scholarly journals Relationship of Type 2 Diabetes Mellitus Duration with The Occurrence of Erectile Dysfunction at Puskesmas Denpasar Barat I

2021 ◽  
Vol 2 (1) ◽  
pp. 23-28
Author(s):  
Alexander Petra Sihite ◽  
I Gusti Ngurah Pramesemara ◽  
I Wayan Surudarma
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Cross Sectional ◽  
Type 2 Dm ◽  
Number Of Patients ◽  
Relationship Of ◽  
The Relationship

Background: Type 2 diabetes mellitus is a metabolic disease that characterized by high blood sugar levels. This condition is often not noticed immediately and usually patient starting to realize it when complications have been occurred. A long-term complication of type 2 DM that occurred in men is erectile dysfunction (ED). ED is a condition when a person is unable to achieve or maintain an erection for sexual intercourse. One factor that influence the occurrence of ED and its severity in type 2 DM patients is the duration of the disease. Objective: The aim of this study was to determine the relationship of type 2 DM duration and the occurrence of ED. Methods: This study is an observational analytic cross-sectional study conducted at the Puskesmas (Public Health Center) Denpasar Barat I. The research data was obtained through medical record data and fill the International Index of Erectile Function (IIEF-5) questionnaire on 36 type 2 DM patients aged around 40-60 years. The statistical analysis used was Fisher's exact test. Results: The results showed that of the 36 samples, 19 (52.8%) samples had type 2 DM <24 months and 17 (47.2%) samples had type 2 DM >24 months. It was found that 5 (13.9%) samples did not experience ED while the rest experienced ED with different severity. There was a significant relationship between the type 2 DM duration and the occurrence of erectile dysfunction at Puskesmas Denpasar Barat I (p = 0.022). Conclusion: Study has found that type 2 DM patients with the longer duration (>24 months)  have a higher occurrence of ED and tended to be more severe compared to those with shorter duration (<24 months). Further studies should be performed with higher number of patients and more controlled risk factor so it will be more accurate in determining the relationship between the duration of type 2 DM and ED.

Sign in / Sign up

Export Citation Format

Share Document